Retrospective, Observational Evaluation of the Utilization, Outcomes, and Adverse Events Associated With Orbactiv for the Treatment of Infections Presumed or Confirmed to be Caused by Gram Positive Bacteria in a Real World Setting
Phase of Trial: Phase IV
Latest Information Update: 13 Mar 2018
Price : $35 *
At a glance
- Drugs Oritavancin (Primary)
- Indications Gram-positive infections
- Focus Therapeutic Use
- Sponsors Melinta Therapeutics; The Medicines Company
- 08 Mar 2018 Status changed from active, no longer recruiting to completed.
- 13 Nov 2017 Planned End Date changed from 1 Oct 2017 to 1 Nov 2017.
- 13 Nov 2017 Planned primary completion date changed from 1 Oct 2017 to 1 Nov 2017.